High-dose carteolol (10.0 mg/kg twice daily) reduced mortality to 22% compared to 59% in untreated turkey poults with furazolidone-induced dilated cardiomyopathy.
Absolute Event Rate: 22% vs 59%
Broad-breasted white turkey poults fed furazolidone developed dilated cardiomyopathy (DCM) characterized by ventricular dilatation, decreased ejection fraction, beta1-receptor density, sarcoplasmic reticulum (SR) Ca2+-ATPase, myofibrillar ATPase activity, and reduced metabolism markers. We investigated the effects of carteolol, a beta-adrenergic blocking agent, by administrating two different dosages (0.01 and 10.0 mg/kg) twice a day for 4 wk to control and DCM turkey poults. At completion of the study there was 59% mortality in the nontreated DCM group, 55% mortality in the group treated with the low dose of carteolol, and 22% mortality in the group treated with the high dose of carteolol. Both treated groups showed a significant decrease in left ventricle size and significant restoration of ejection fraction and left ventricular peak systolic pressure. Carteolol treatment increased beta-adrenergic receptor density, and the high carteolol dose restored SR Ca2+-ATPase and myofibrillar ATPase activities, along with creatine kinase, lactate dehydrogenase, aspartate transaminase, and ATP synthase activities, to normal. These results show that beta-blockade with carteolol improves survival, reverses contractile abnormalities, and induces cellular remodeling in this model of heart failure.
Gwathmey et al. (Sat,) conducted a other in Dilated cardiomyopathy (DCM). Carteolol vs. Nontreated DCM group was evaluated on Mortality. High-dose carteolol (10.0 mg/kg twice daily) reduced mortality to 22% compared to 59% in untreated turkey poults with furazolidone-induced dilated cardiomyopathy.